Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

41. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial (PubMed)

Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial To evaluate whether therapy with sildenafil citrate prolongs gestation in women with preeclampsia.In a randomized double-blind, placebo-controlled trial, 100 singleton pregnancies with preeclampsia between 24 and 33 weeks of gestation were randomized to 50 mg oral sildenafil citrate every 8 hours or placebo. The primary outcome was prolongation of pregnancy from randomization

2016 EvidenceUpdates

42. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis (PubMed)

LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis Placental mediated pregnancy complications such as preeclampsia and fetal growth restriction (FGR) are common, serious, and associated with increased morbidity and mortality. We conducted a systematic review and meta-analysis to determine the effect of treatment with low-molecular-weight heparins (LMWHs) for secondary prevention of these complications in non (...) thrombophilic women. We searched the electronic databases PubMed, Scopus, and Cochrane Library for randomised controlled trials addressing this question. Five studies including 403 patients met the inclusion criteria, 68 developed preeclampsia and 118 FGR. The studies were very heterogeneous in terms of inclusion criteria, LMWH preparation, and dosage. Meta-analyses were performed using random-effect models. The overall use of LMWHs was associated with a risk reduction for preeclampsia (Relative risk (RR

2016 EvidenceUpdates

43. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia (PubMed)

Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia To assess the association of a serum soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1-to-PlGF) ratio of greater than 38 with time to delivery and preterm birth.Secondary analysis of an observational cohort study that included women 18 years of age or older from 24 to 36 6/7 weeks of gestation at their first study visit with suspected (not confirmed (...) ) preeclampsia. Participants were recruited from December 2010 to January 2014 at 30 sites in 14 countries. A total of 1,041 women were included in time-to-delivery analysis and 848 in preterm birth analysis.Women with an sFlt-1-to-PlGF ratio greater than 38 (n=250) had a 2.9-fold greater likelihood of imminent delivery (ie, delivery on the day of the test) (Cox regression hazard ratio 2.9; P<.001) and shorter remaining time to delivery (median 17 [interquartile range 10-26] compared with 51 [interquartile

2016 EvidenceUpdates

44. The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia. (PubMed)

The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia. Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug.To determine the impact of Silymarin on the improvement of severe preeclampsia in 60 patients with severe preeclampsia.In (...) this double-blind clinical trial study, This study included 60 patients whose pregnancies were terminated because of severe preeclampsia and who were referred to Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. The patients were divided randomly into two groups, i.e., a group of 30 patients and a control group of 30 patients. In addition to the current treatments for preeclampsia, The members of the study group were administered 70 mg of Silymarin at three hours and 24 hours after

Full Text available with Trip Pro

2016 Electronic physician

45. Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications (PubMed)

Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications Up until now there have been contradictory data about the association between p.Val158Met catechol-O-methyltransferase (COMT) polymorphism and risk of preeclampsia (PE). The goal of this study was to assess the potential correlation between p.Val158Met COMT polymorphism and risk of early-onset PE, risk of a severe form of early-onset PE, as well as risk

Full Text available with Trip Pro

2016 Journal of medical biochemistry

46. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. (PubMed)

The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 27144854 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 1785-6 10.1056/NEJMc1602338 Zeisler Harald H Hund Martin M Verlohren Stefan S eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Pregnancy Proteins EC 2.7.10.1 Vascular Endothelial Growth Factor Receptor-1 AIM IM N Engl J Med. 2016 Jan 7;374(1):13-22

Full Text available with Trip Pro

2016 NEJM

47. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. (PubMed)

The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 27144855 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 1785 10.1056/NEJMc1602338 Bolla Daniele D University Hospital of Bern, Bern, Switzerland daniele.bolla@insel.ch. Papadia Andrea A University Hospital of Bern, Bern, Switzerland daniele.bolla@insel.ch. Raio Luigi L University Hospital of Bern, Bern, Switzerland

Full Text available with Trip Pro

2016 NEJM

48. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. (PubMed)

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in women with suspected preeclampsia is unclear.We performed a prospective, multicenter, observational study to derive and validate a ratio of serum sFlt-1 to PlGF that would be predictive of the absence or presence (...) of preeclampsia in the short term in women with singleton pregnancies in whom preeclampsia was suspected (24 weeks 0 days to 36 weeks 6 days of gestation). Primary objectives were to assess whether low sFlt-1:PlGF ratios (at or below a derived cutoff) predict the absence of preeclampsia within 1 week after the first visit and whether high ratios (above the cutoff) predict the presence of preeclampsia within 4 weeks.In the development cohort (500 women), we identified an sFlt-1:PlGF ratio cutoff of 38

2016 NEJM

49. Improving the Prediction of Preeclampsia. (PubMed)

Improving the Prediction of Preeclampsia. 26735997 2016 01 20 2018 12 02 1533-4406 374 1 2016 Jan 07 The New England journal of medicine N. Engl. J. Med. Improving the Prediction of Preeclampsia. 83-4 10.1056/NEJMe1515223 Seely Ellen W EW From the Endocrinology, Diabetes, and Hypertension Division, Brigham and Women's Hospital, Boston (E.W.S.). Solomon Caren G CG eng Editorial Comment United States N Engl J Med 0255562 0028-4793 0 Pregnancy Proteins EC 2.7.10.1 Vascular Endothelial Growth

2016 NEJM

50. Association Between Preeclampsia and Congenital Heart Defects. (PubMed)

Association Between Preeclampsia and Congenital Heart Defects. The risk of congenital heart defects in infants of women who had preeclampsia during pregnancy is poorly understood, despite shared angiogenic pathways in both conditions.To determine the prevalence of congenital heart defects in offspring of women with preeclampsia.Population-level analysis of live births before discharge, 1989-2012, was conducted for the entire province of Quebec, comprising a quarter of Canada's population. All (...) women who delivered an infant with or without heart defects in any Quebec hospital were included (N = 1,942,072 neonates).Preeclampsia or eclampsia with onset before or after 34 weeks of gestation.Presence of any critical or noncritical congenital heart defect detected in infants at birth, comparing prevalence in those exposed and not exposed to preeclampsia.The absolute prevalence of congenital heart defects was higher for infants of women with preeclampsia than those without it. Infants of women

Full Text available with Trip Pro

2015 JAMA

51. Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Article Text Midwifery Systematic review with meta-analysis Low-dose

2015 Evidence-Based Nursing

52. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Free Paul Leeson Statistics from Altmetric.com Commentary on : Henderson JT , Whitlock EP , O'Connor E , et al . Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task

Full Text available with Trip Pro

2015 Evidence-Based Medicine (Requires free registration)

53. Gestational Hypertension and Preeclampsia in Living Kidney Donors. (PubMed)

Gestational Hypertension and Preeclampsia in Living Kidney Donors. Young women wishing to become living kidney donors frequently ask whether nephrectomy will affect their future pregnancies.We conducted a retrospective cohort study of living kidney donors involving 85 women (131 pregnancies after cohort entry) who were matched in a 1:6 ratio with 510 healthy nondonors from the general population (788 pregnancies after cohort entry). Kidney donations occurred between 1992 and 2009 in Ontario (...) , Canada, with follow-up through linked health care databases until March 2013. Donors and nondonors were matched with respect to age, year of cohort entry, residency (urban or rural), income, number of pregnancies before cohort entry, and the time to the first pregnancy after cohort entry. The primary outcome was a hospital diagnosis of gestational hypertension or preeclampsia. Secondary outcomes were each component of the primary outcome examined separately and other maternal and fetal

Full Text available with Trip Pro

2014 NEJM

54. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. (PubMed)

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy.The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed the maternal and fetal harms (...) of low-dose aspirin during pregnancy.This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin.The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

Full Text available with Trip Pro

2014 Annals of Internal Medicine

55. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. (PubMed)

Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality.To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia.MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled Trials (January 2006 to June 2013 (...) ); previous systematic reviews, clinical trial registries, and surveillance searches for large studies (June 2013 to February 2014).Randomized, controlled trials (RCTs) to assess benefits among women at high preeclampsia risk and RCTs or large cohort studies of harms among women at any risk level. English-language studies of fair or good quality were included.Dual quality assessment and abstraction of studies.Two large, multisite RCTs and 13 smaller RCTs of high-risk women (8 good-quality) were included

2014 Annals of Internal Medicine

56. Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia

Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia UTCAT2704, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia Clinical Question Is periodontitis a risk factor for development of preeclampsia during pregnancy? Clinical Bottom Line Research has shown that periodontal disease (...) contributes to the development of preeclampsia during pregnancy. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Sgolastra/2013 384 studies Meta-Analysis Key results This meta-analysis concluded that a relationship between pregnant women with periodontal disease (PD) and development of preeclampsia (PE) does indeed exist. Originally, 384 studies were reviewed; however, only 15 studies qualified for inclusion

2014 UTHSCSA Dental School CAT Library

57. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication Final Update Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive (...) Medication Release Date: September 2014 Recommendation Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia Population Recommendation Grade Pregnant Women Who Are At High Risk for Preeclampsia The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information

2014 U.S. Preventive Services Task Force

58. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms (PubMed)

Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms To evaluate two algorithms for prediction of preeclampsia in a population of nulliparous women in Norway.Prospective screening study.National Centre for Fetal Medicine in Trondheim, Norway.Five hundred and forty-one nulliparous women.The women were examined between 11(+0) and 13(+6) weeks with interviews for maternal characteristics and measurements of mean arterial (...) pressure, uterine artery pulsatility index, pregnancy-associated plasma protein A and placental growth factor. The First Trimester Screening Program version 2.8 by The Fetal Medicine Foundation (FMF) was compared with the Preeclampsia Predictor TM version 1 revision 2 by Perkin Elmer (PREDICTOR).Prediction of preeclampsia requiring delivery before 37 weeks, before 42 weeks and late preeclampsia (delivery after 34 weeks).The performance of the two algorithms was similar, but quite poor, for prediction

Full Text available with Trip Pro

2014 EvidenceUpdates

59. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial (PubMed)

Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial The objective of the study was to determine whether expectant management of severe preeclampsia prior to 34 weeks of gestation results in improved neonatal outcome in countries with limited resources.This was a randomized clinical trial performed in 8 tertiary hospitals in Latin America. Criteria of randomization included gestational age between 28 and 33 weeks (...) % CI, 1.13-22.7; P = .01). There were no maternal deaths.This study does not demonstrate neonatal benefit with expectant management of severe preeclampsia from 28 to 34 weeks. Additionally, a conservative approach may increase the risk of abruption and small for gestational age.Copyright © 2013 Mosby, Inc. All rights reserved.

2014 EvidenceUpdates

60. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study (PubMed)

Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental (...) dysfunction in preeclampsia, with known low plasma concentrations in the disease.In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a secondary analysis). The outcome was delivery for confirmed preeclampsia within 14 days. Of 625 women, 346 (55%) developed confirmed preeclampsia. In 287

Full Text available with Trip Pro

2013 EvidenceUpdates